Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by KBC Group NV

KBC Group NV grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 79.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,602 shares of the company’s stock after purchasing an additional 3,377 shares during the period. KBC Group NV’s holdings in Recursion Pharmaceuticals were worth $50,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter valued at approximately $25,000. Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the last quarter. Finally, San Luis Wealth Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at $69,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $5.70 on Friday. The stock has a 50-day simple moving average of $6.62 and a 200-day simple moving average of $7.50. The firm has a market cap of $1.63 billion, a P/E ratio of -3.73 and a beta of 0.81. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same period in the prior year, the business earned ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the completion of the transaction, the chief financial officer now owns 1,377,756 shares in the company, valued at approximately $8,500,754.52. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at $4,606,442.24. This trade represents a 2.56 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 171,682 shares of company stock worth $1,133,471 over the last quarter. 15.75% of the stock is owned by company insiders.

Analyst Ratings Changes

RXRX has been the topic of several recent analyst reports. Jefferies Financial Group reduced their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday. Finally, Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $9.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.